Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer-Reference-Cited by-同舟云学术

Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer

Published:2021-06-01 Issue:6 Volume:7 Page:869
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Hall Peter S.¹²,Swinson Daniel³,Cairns David A.¹,Waters Justin S.⁴,Petty Russell⁵,Allmark Christine,Ruddock Sharon¹,Falk Stephen⁶,Wadsley Jonathan⁷,Roy Rajarshi⁸,Tillett Tania⁹,Nicoll Jonathan¹⁰,Cummins Sebastian¹¹,Mano Joseph¹²,Grumett Simon¹³,Stokes Zuzana¹⁴,Kamposioras Konstantinos-Velios¹⁵,Chatterjee Anirban¹⁶,Garcia Angel¹⁷,Waddell Tom¹⁸,Guptal Kamalnayan¹⁹,Maisey Nick²⁰,Khan Mohammed²¹,Dent Jo²²,Lord Simon²³,Crossley Ann³,Katona Eszter¹,Marshall Helen¹,Grabsch Heike I.¹²⁴,Velikova Galina¹,Ow Pei Loo¹,Handforth Catherine¹,Howard Helen¹,Seymour Matthew T.¹³,James Eleanor²⁵,Cheeseman Sue²⁵,Roques Tom²⁵,Reed Nick²⁵,Candish Charles²⁵,Fyfe David²⁵,Last Kim²⁵,Ellis Richard²⁵,Samuel Lesley²⁵,Herbertson Rebecca²⁵,Medley Louise²⁵,Patel Kinnari²⁵,Sherriff David²⁵,Robinson Angus²⁵,Bezecny Pavel²⁵,Wilkins Dunca²⁵,McGeoch Adam²⁵,Propper Daniel²⁵,Williams Olwyn²⁵,Hilman Serena²⁵,Raouf Sherif²⁵,Hobbs Claire²⁵,Parkinson Jo²⁵,Wadd Nick²⁵,Saku W²⁵,Kunene Victori²⁵,Askill Colin²⁵,Jamil Arshad²⁵,Cattell Emma²⁵,Gorf Lauren²⁵,Vigneswaran Vallipuram²⁵,Beaumont Erica²⁵,Zubair Syed²⁵,Jones Elin²⁵,Reed Nicholas²⁵,Shablak Alaaeldin²⁵,Bozas George²⁵,Rao Sheela²⁵,Bennet Michael²⁵,Askey Joanne²⁵,Griffiths Gareth²⁵,Clive Sally²⁵,Potter Vanessa²⁵,Gall Jean²⁵,Twelves Chris²⁵,Sydes Matt²⁵,Valle Juan²⁵,Webster Jo²⁵,Jones Marc²⁵,Collinson Fiona²⁵,Brown Julia²⁵,Brook Louise²⁵,

Affiliation:

1. University of Leeds, Leeds, United Kingdom

2. University of Edinburgh, Edinburgh, United Kingdom

3. Leeds Teaching Hospitals National Health Service Trust, United Kingdom

4. Maidstone and Tunbridge Wells National Health Service Trust, Maidstone, United Kingdom

5. University of Dundee, Dundee, United Kingdom

6. Bristol Oncology Centre, Bristol, United Kingdom

7. Weston Park Cancer Centre, Sheffield, United Kingdom

8. Hull University Hospitals National Health Service Trust, Hull, United Kingdom

9. Royal United Hospitals Bath, Bath, United Kingdom

10. North Cumbria University Hospitals National Health Service Trust, Carlisle, United Kingdom

11. Royal Surrey County Hospital National Health Service Foundation Trust, Guildford, United Kingdom

12. The Royal Wolverhampton National Health Service Trust, Wolverhampton, United Kingdom

13. The Dudley Group National Health Service Foundation Trust, Dudley, United Kingdom

14. United Lincolnshire Hospitals National Health Service Trust, Lincoln, United Kingdom

15. Mid Yorkshire Hospitals National Health Service Trust, Wakefield, United Kingdom

16. The Shrewsbury and Telford Hospital National Health Service Trust, Shrewsbury, United Kingdom

17. Betsi Cadwaladr University Local Health Board, Bangor, United Kingdom

18. The Christie National Health Service Foundation Trust, Manchester, United Kingdom

19. Worcestershire Acute Hospitals National Health Service Trust, Worcester, United Kingdom

20. Guys and St Thomas’s National Health Service Foundation Trust, London, United Kingdom

21. York Teaching Hospital National Health Service Foundation Trust, Scarborough, United Kingdom

22. Calderdale and Huddersfield National Health Service Foundation Trust, Huddersfield, United Kingdom

23. University of Oxford, Oxford, United Kingdom

24. Maastricht University Medical Center, Maastricht, the Netherlands

25. for the GO2 Trial Investigators

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/articlepdf/2780033/jamaoncology_hall_2021_oi_210009_1624469496.87358.pdf

Reference31 articles.

1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.;Ferlay;Int J Cancer,2015

2. Capecitabine and oxaliplatin for advanced esophagogastric cancer.;Cunningham;N Engl J Med,2008

3. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.;Al-Batran;Ann Oncol,2008

4. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.;Van Cutsem;J Clin Oncol,2006

5. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study.;Guimbaud;J ClinOncol,2014

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902);International Journal of Clinical Oncology;2024-01-16

2. Efficacy and safety of systemic chemotherapy for radically resectable esophago-gastric adenocarcinoma in older patients: A systematic review and meta-analysis;Journal of Geriatric Oncology;2024-01

3. Emerging Targets for Systemic Treatment of Gastric Cancer: HER2 and Beyond;Journal of Gastric Cancer;2024

4. Global status of research on gastrointestinal cancer patients’ quality of life: A bibliometric and visual analysis from 2003 to 2023;Heliyon;2024-01

5. Big Data and Colorectal Cancer: the Revolution will be Personalised;Clinical Oncology;2024-01